Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Recommendation of “Buy” by Brokerages

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have earned a consensus rating of “Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $209.1429.

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, August 5th.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $157.24 on Tuesday. The business’s fifty day simple moving average is $148.40 and its 200 day simple moving average is $130.34. The firm has a market capitalization of $2.27 billion, a P/E ratio of -32.55 and a beta of -0.25. Palvella Therapeutics has a 12 month low of $52.36 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Analysts predict that Palvella Therapeutics will post -6.36 EPS for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $327,860.34. This represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the sale, the director directly owned 250 shares of the company’s stock, valued at $39,250. This represents a 55.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 8,917 shares of company stock valued at $1,180,309. 17.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Palvella Therapeutics during the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $35,000. Group One Trading LLC raised its position in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $36,000. Finally, Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at approximately $69,000. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.